Aberrant expression of an "intestinal marker" Cdx2 in pyloric gland adenoma of the gallbladder

Yoji Wani, Kenji Notohara, Masayoshi Fujisawa

Research output: Contribution to journalArticle

17 Citations (Scopus)


The aim of this study was to survey Cdx2 expression in pyloric gland adenoma (PGA) of the gallbladder. We reviewed 29 PGA cases, ten (34.4%) and seven (24.1%) of which showed intestinal metaplasia (IM) and squamous morule (SM), respectively. The immunostaining for Cdx2, beta-catenin, MUC5AC, MUC2, MUC6, and M-GGMC-1 was performed and scored (0 = negative, 1+ = <10%, 2+ = 10% to <30%, 3+ = 30% to <50%, 4+ = 50% to <70%, 5+ = 70-100%). Although its scores were relatively low (1+ or 2+), Cdx2 was frequently expressed in 27 cases (93.1%). Not only goblet and/or Paneth cells were positive but also non-IM cells in PGAs, as opposed to the lack of staining in the background mucosa. Cdx2 scores were not correlated with those of IM (p = 0.485) and MUC2 (p = 0.868). Of note, Cdx2 was positive in foci of SM in all seven cases, and there was a significant difference in Cdx2 scores between PGAs with and without SM. Furthermore, the p value of scores between Cdx2 and beta-catenin was 0.051, and both mean labeling indices (LIs) were correlated (r = 0.736). With Cdx2, higher morular LIs than glandular LIs were observed (p = 0.001). Finally, we concluded that aberrant Cdx2 expression in PGAs is closely associated with nuclear beta-catenin expression and SM in contrast with IM.

Original languageEnglish
Pages (from-to)521-527
Number of pages7
JournalVirchows Archiv
Issue number5
Publication statusPublished - Nov 1 2008
Externally publishedYes


  • Beta-catenin
  • Cdx2
  • Gallbladder
  • Immunohistochemistry
  • Pyloric gland adenoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Aberrant expression of an "intestinal marker" Cdx2 in pyloric gland adenoma of the gallbladder'. Together they form a unique fingerprint.

  • Cite this